22nd Century Group, Inc.
corporate_fare Company Profile
22nd Century Group, Inc. (NASDAQ:XXII) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for XXII at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-28, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for XXII spans 10-Q, 424B3, 8-K, DEF 14A.
Recent high-impact activity:
- French Health Agency Backs Nicotine Caps, Citing 22nd Century's Tech as Only Commercial Path
- 22nd Century Group Q2 2026: Revenue Down 30%, Going Concern Doubt, Warrant Overhang
- 22nd Century Group Slashes Warrant Exercise Price to $0.3675, Adds Cashless Exercise
- 22nd Century Q2 Revenue Falls 30% to $2.9M as Product Shift Bites
- 22nd Century Posts Q2 Loss While Expanding VLN Retail Presence
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 38,033 shares in XXII as of the September 15, 2026 settlement, a 11.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 40.9% of XXII volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for XXII, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.
Warrant Exercise Price Slashed 91% · Cashless Exercise Now Allowed
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →